Paul Hudson

Paul Hudson drove Sanofi’s transformation into a biopharma company focused on new drug development. He spun off Sanofi’s consumer health care business (rebranded as Opella), allowing Sanofi to concentrate resources and leadership on its core biopharma operations. His ambition for Sanofi to become a global leader in immunology remains central. The company has delivered strong double-digit sales growth throughout 2024, propelled by the asthma drug Dupixent, among other treatments, and a strong development pipeline.